Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmaceutical products. Its products include improved cell-permeable parkin (iCP-Parkin), cell/tissue permeable frataxin (CP-FXN), improved cell-permeable SOCS3 (iCP-SOCS3), cell-permeable BMP2 (CP-BMP2), cell-permeable truncated SOCS3 (CP-SD), improved cell-permeable nuclear import inhibitor (iCP-NI), and others. The company was founded by Dae-Woong Cho on March 14, 2014 and is headquartered in Seoul, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Revenue streams and regions a business earns money from
Dividend yield, history and sustainability
Financial position and solvency of the company